Nicole Mifsud

Dr. Nicole Mifsud

Monash University, Clayton, Victoria 3800, Australia
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Immunity
Verified
Journal Article
Closed access
DCDiana Chessman
Diana Chessman
LKLyudmila Kostenko
Lyudmila Kostenko
TLTessa Lethborg
Tessa Lethborg
Anthony PurcellAnthony Purcell
Anthony Purcell
NWNicholas Williamson
Nicholas Williamson
JMJames McCluskey
James McCluskey

18 February 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
MKMarios Koutsakos
Marios Koutsakos
PIPatricia Illing
Patricia Illing
TNThi H. O. Nguyen
Thi H. O. Nguyen
NMNicole Mifsud
Nicole Mifsud
JCJeremy Chase Crawford
Jeremy Chase Crawford
KKKatherine Kedzierska
Katherine Kedzierska

25 August 2003 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
WMWhitney A. Macdonald
Whitney A. Macdonald
Anthony PurcellAnthony Purcell
Anthony Purcell
NMNicole Mifsud
Nicole Mifsud
LELauren K. Ely
Lauren K. Ely
DWDavid S. Williams
David S. Williams
JMJames McCluskey
James McCluskey
HLA-B*4402 and B*4403 are naturally occurring MHC class I alleles that are both found at a high frequency in all human populations, and yet they only differ by one residue on the α2 helix (B*4402 Asp156→B*4403 Leu156). CTLs discriminate between HLA-B*4402 and B*4403, and these allotypes stimulate strong mutual allogeneic responses reflecting their known barrier to hemopoeitic stem cell transplantation. Although HLA-B*4402 and B*4403 share >95% of their peptide repertoire, B*4403 presents more unique peptides than B*4402, consistent with the stronger T cell alloreactivity observed toward B*4403 compared with B*4402. Crystal structures of B*4402 and B*4403 show how the polymorphism at position 156 is completely buried and yet alters both the peptide and the heavy chain conformation, relaxing ligand selection by B*4403 compared with B*4402. Thus, the polymorphism between HLA-B*4402 and B*4403 modifies both peptide repertoire and T cell recognition, and is reflected in the paradoxically powerful alloreactivity that occurs across this “minimal” mismatch. The findings suggest that these closely related class I genes are maintained in diverse human populations through their differential impact on the selection of peptide ligands and the T cell repertoire.

10 May 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LKLars Kjer-Nielsen
Lars Kjer-Nielsen
Michelle DunstoneMichelle Dunstone
Michelle Dunstone
LKLyudmila Kostenko
Lyudmila Kostenko
LELauren K. Ely
Lauren K. Ely
Travis BeddoeTravis Beddoe
Travis Beddoe
JRJamie Rossjohn
Jamie Rossjohn
The CD3εγ heterodimer is essential for expression and function of the T cell receptor. The crystal structure of the human CD3εγ heterodimer is described to 2.1-Å resolution complexed with OKT3, a therapeutic mAb that not only activates and tolerizes mature T cells but also induces regulatory T cells. The mode of CD3εγ dimerization provides a general structural basis for CD3 assembly and maps candidate T cell antigen receptor docking sites, including a duplicated linear region rich in acidic residues that is unique to human CD3ε. OKT3 binds to an atypically small area of CD3ε and has a low affinity for the isolated CD3εγ heterodimer. The structure of the OKT3/CD3εγ complex has implications for T cell signaling and therapeutic design.

28 June 2004 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DZDanielle Zernich
Danielle Zernich
Anthony PurcellAnthony Purcell
Anthony Purcell
WMWhitney A. Macdonald
Whitney A. Macdonald
LKLars Kjer-Nielsen
Lars Kjer-Nielsen
LELauren K. Ely
Lauren K. Ely
JMJames McCluskey
James McCluskey
HLA class I polymorphism creates diversity in epitope specificity and T cell repertoire. We show that HLA polymorphism also controls the choice of Ag presentation pathway. A single amino acid polymorphism that distinguishes HLA-B*4402 (Asp116) from B*4405 (Tyr116) permits B*4405 to constitutively acquire peptides without any detectable incorporation into the transporter associated with Ag presentation (TAP)-associated peptide loading complex even under conditions of extreme peptide starvation. This mode of peptide capture is less susceptible to viral interference than the conventional loading pathway used by HLA-B*4402 that involves assembly of class I molecules within the peptide loading complex. Thus, B*4402 and B*4405 are at opposite extremes of a natural spectrum in HLA class I dependence on the PLC for Ag presentation. These findings unveil a new layer of MHC polymorphism that affects the generic pathway of Ag loading, revealing an unsuspected evolutionary trade-off in selection for optimal HLA class I loading versus effective pathogen evasion.

26 October 2018 in Science Immunology
Verified
Journal Article
Closed access
PDF file
Pouya FaridiPouya Faridi
Pouya Faridi
CLChen Li
Chen Li
SRSri H. Ramarathinam
Sri H. Ramarathinam
JVJulian P. Vivian
Julian P. Vivian
PIPatricia Illing
Patricia Illing
Anthony PurcellAnthony Purcell
Anthony Purcell
A considerable proportion of HLA-I peptides likely derive from cis- and trans-splicing events.